Valuation: Seres Therapeutics, Inc.

Market Cap 4.31Cr 3.73Cr 3.51Cr 3.19Cr 5.99Cr 413.39Cr 6.08Cr 41Cr 16Cr 206.75Cr 16Cr 16Cr 688.67Cr P/E 2026 *
-1.23x
P/E 2027 * -0.88x
Enterprise Value 4.31Cr 3.73Cr 3.51Cr 3.19Cr 5.99Cr 413.39Cr 6.08Cr 41Cr 16Cr 206.75Cr 16Cr 16Cr 688.67Cr EV / Sales 2026 *
3.13x
EV / Sales 2027 * 158x
Free-Float
88.52%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day+2.76%
1 week-6.73%
Current month-8.85%
1 month-13.85%
3 months-40.83%
6 months-49.63%
Current year-70.41%
1 week 4.32
Extreme 4.315
4.75
1 month 4.32
Extreme 4.315
5.65
Current year 4.32
Extreme 4.315
16.42
1 year 4.32
Extreme 4.315
29.98
3 years 4.32
Extreme 4.315
73.4
5 years 4.32
Extreme 4.315
233.8
10 years 4.32
Extreme 4.315
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
Chief Executive Officer 58 01/08/2025
President 51 02/03/2026
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap.
08/07/26 Free

General Counsel

7,500 0.0774%
08/07/26 Free

Director

6,500 0.0671%
08/07/26 Free

Director

6,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
+2.76%-6.73%-72.91%-93.83% 4.31Cr
-1.90%+2.37%+69.11%+110.88% 7.35TCr
+0.87%+15.32%+56.99%+92.41% 6.3TCr
-0.26%-3.03%+0.83%+483.05% 2.81TCr
-1.40%+4.18%+54.52%+19.60% 2.54TCr
+20.82%+19.57%-0.46%-5.65% 2.33TCr
+2.28%+5.65%+42.00%-13.75% 1.95TCr
0.00%-4.11%+243.99%+423.83% 1.82TCr
-3.50%-0.95%+17.17%+534.55% 1.65TCr
+1.89%+7.37%+44.18%+153.14% 1.32TCr
Average +2.16%+1.82%+45.54%+170.42% 2.81TCr
Weighted average by Cap. +1.32%+4.38%+57.65%+164.53%

Financials

2026 *2027 *
Net sales 1.38Cr 1.19Cr 1.12Cr 1.02Cr 1.92Cr 132.19Cr 1.94Cr 13Cr 5.15Cr 66Cr 5.18Cr 5.07Cr 220.22Cr 3L 2L 2L 2L 4L 2.62Cr 4L 26.07L 10.22L 1.31Cr 10.27L 10.05L 4.37Cr
Net income -3.75Cr -3.24Cr -3.05Cr -2.77Cr -5.21Cr -359.19Cr -5.28Cr -36Cr -14Cr -179.64Cr -14Cr -14Cr -598.37Cr -7.9Cr -6.82Cr -6.42Cr -5.83Cr -11Cr -756.49Cr -11Cr -75Cr -29Cr -378.35Cr -30Cr -29Cr -1.26TCr
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
19/26/19 $4.403 +1.44% 33,346
18/26/18 $4.340 -3.77% 71,418
17/26/17 $4.510 -0.66% 42,185
14/26/14 $4.540 +1.34% 37,281
13/26/13 $4.480 -5.08% 81,900
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.340USD
Average target price
17.00USD
Spread / Average Target
+291.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock